Figure 3.

Cumulative incidence of Child–Pugh deterioration stratified by first treatment methods, i.e., curative therapy (a) and TACE (b). In curative therapy, five-year cumulative incidence rates of antiplatelet therapy (dotted line) and no antiplatelet therapy (solid line) were 30.0% and 48.6%, respectively (p = 0.08). In TACE (b), five-year cumulative incidence rates of antiplatelet therapy (dotted line) and no antiplatelet therapy (solid line) were 59.6% and 82.4%, respectively (p < 0.001).